Aceclidine

Generic Name: Aceclidine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₅NO_₂

CAS Number: 827-61-2

Unique Ingredient Identifier: 0578K3ELIO

Background: Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.

Indication: 滴眼给药用于青光眼。

Clinical Trials

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

Phase 3

Completed

Conditions: Presbyopia
Near Vision
Miosis
Eye Diseases

Interventions: Drug: Aceclidine ophthalmic solution
Drug: Placebo (Vehicle) ophthalmic solution
Drug: Aceclidine+Brimonidine combination ophthalmic solution

First Posted Date: 2023-09-21

Last Posted Date: 2025-03-03

Lead Sponsor: Corxel Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06045299

Locations: 🇨🇳
Dalian N0.3 people's hospital, Dalian, China
🇨🇳
Guang Zhou Aier eye Hospital, Guangzhou, China
🇨🇳
Henan Eye Hospital & Henan Institute, Zhengzhou, China

and more 16 locations

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Phase 1

Completed

Conditions: Ophthalmic Solutions
Presbyopia
Refractive Errors
Eye Diseases
Brimonidine Tartrate
Aceclidine

Interventions: Drug: Aceclidine + Brimonidine
Drug: Aceclidine

First Posted Date: 2023-07-07

Last Posted Date: 2023-10-16

Lead Sponsor: LENZ Therapeutics, Inc

Target Recruit Count: 30

Registration Number: NCT05936489

Locations: 🇺🇸
Site #101, Newport Beach, California, United States

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Phase 3

Completed

Conditions: Eye Diseases
Near Vision
Miosis
Presbyopia

Interventions: Drug: Placebo
Drug: Aceclidine Ophthalmic Solution
Drug: Aceclidine+Brimonidine combination ophthalmic solution

First Posted Date: 2023-03-03

Last Posted Date: 2024-12-18

Lead Sponsor: LENZ Therapeutics, Inc

Target Recruit Count: 362

Registration Number: NCT05753189

Locations: 🇺🇸
Site #304, Santa Barbara, California, United States
🇺🇸
Site #312, Cranberry Township, Pennsylvania, United States
🇺🇸
Site #311, Smyrna, Tennessee, United States

and more 33 locations

Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia

Phase 3

Completed

Conditions: Presbyopia
Miosis
Near Vision
Eye Diseases

Interventions: Drug: Vehicle
Drug: Aceclidine+Brimonidine combination ophthalmic solution
Drug: Aceclidine

First Posted Date: 2023-02-15

Last Posted Date: 2024-12-18

Lead Sponsor: LENZ Therapeutics, Inc

Target Recruit Count: 229

Registration Number: NCT05728944

Locations: 🇺🇸
Site #215, Bozeman, Montana, United States
🇺🇸
Site #216, Scottsdale, Arizona, United States
🇺🇸
Site #209, Dothan, Alabama, United States

and more 10 locations

Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Phase 3

Completed

Conditions: Presbyopia
Refractive Error
Near Vision
Miosis
Eye Diseases

Interventions: Drug: Aceclidine + Brimonidine
Drug: Aceclidine
Drug: Brimonidine

First Posted Date: 2022-12-19

Last Posted Date: 2024-12-18

Lead Sponsor: LENZ Therapeutics, Inc

Target Recruit Count: 469

Registration Number: NCT05656027

Locations: 🇺🇸
Site #121, Mesa, Arizona, United States
🇺🇸
Site #104, Fargo, North Dakota, United States
🇺🇸
Site #122, Phoenix, Arizona, United States

and more 17 locations

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

Phase 2

Completed

Conditions: Presbyopia
Refractive Errors
Eye Diseases

Interventions: Drug: Aceclidine+Brimonidine combination ophthalmic solution
Drug: Aceclidine ophthalmic solution
Drug: Vehicle proprietary ophthalmic solution

First Posted Date: 2022-06-24

Last Posted Date: 2023-01-11

Lead Sponsor: Alisyn Facemire

Target Recruit Count: 58

Registration Number: NCT05431543

Locations: 🇺🇸
INSIGHT-2 Study Site #4, Houston, Texas, United States
🇺🇸
INSIGHT-2 Study Site #3, Glendale, California, United States
🇺🇸
INSIGHT-2 Study Site #1, Andover, Massachusetts, United States

and more 2 locations

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Phase 2

Completed

Conditions: Presbyopia
Eye Diseases
Refractive Errors

Interventions: Drug: Aceclidine+Brimonidine combination ophthalmic solution
Drug: Aceclidine ophthalmic solution
Drug: Vehicle Proprietary Ophthalmic Solution

First Posted Date: 2022-03-24

Last Posted Date: 2022-10-19

Lead Sponsor: LENZ Therapeutics, Inc

Target Recruit Count: 62

Registration Number: NCT05294328

Locations: 🇺🇸
INSIGHT-1 Study Site #4, Glendale, California, United States
🇺🇸
INSIGHT-1 Study Site #3, Indianapolis, Indiana, United States
🇺🇸
INSIGHT-1 Study Site #1, Andover, Massachusetts, United States

and more 2 locations

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: Aceclidine+tropicamide combination
Drug: Vehicle
Drug: Aceclidine

First Posted Date: 2017-06-28

Last Posted Date: 2022-09-22

Lead Sponsor: LENZ Therapeutics, Inc

Target Recruit Count: 58

Registration Number: NCT03201562

Locations: 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy